NASDAQ · Biotechnology · USD
60 Degrees Pharmaceuticals, Inc. (SXTP) Stock Analysis
60 Degrees Pharmaceuticals, Inc. (SXTP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
SXTP Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.94
- Previous Close
- $0.92
- Day's Range
- 0.87–0.95
- 52-Week Range
- 0.81–8.62
- Volume
- 24.03K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 2.40
Valuation
- Market Cap
- $3.13M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 2.58
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −5.34
Financials (FY)
- Revenue (FY)
- $1.01M+65.49%
- Net Income (FY)
- −$7.37M
- Shares Outstanding
- 3.52M
- 1-Year Return
- −84.76%
Dividend and dates
- Avg Volume
- 131.37K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, SXTP closed at $0.89, −84.76% over 1 year.
60 Degrees Pharmaceuticals, Inc. (SXTP) has a market capitalization of $3.13M.
In fiscal 2025, SXTP reported revenue of $1.01M.
SXTP Stock Return by Calendar Year
60 Degrees Pharmaceuticals, Inc. (SXTP) return since Jul 2023: what $10,000 became
- 1 year
- $10,000 $1,524
- −84.76%
- 3 years
- $10,000 $50
- −99.50%
- Since Jul 2023
- $10,000 $8
- −99.92%
If you had invested $10,000 in 60 Degrees Pharmaceuticals, Inc. (SXTP) at the close on July 12, 2023, the earliest close on record here, it would have been worth $8 at the close on October 21, 2026: −99.92% in total, −88.68% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −56.20% |
| 2025 | −92.12% |
| 2024 | −89.46% |
| 2023 (partial year) | −78.21% |
As of October 21, 2026.
SXTP Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $1.01M | −$7.37M | −732.5% |
| 2024 | $607.57K | −$7.95M | −1,308.0% |
| 2023 | $253.57K | −$3.77M | −1,485.1% |
| 2022 | $223.21K | −$6.18M | −2,769.5% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $1.01M | $223.78K | −$7.76M | −$7.37M | −732.5% |
| 2024 | $607.57K | $222.81K | −$9.72M | −$7.95M | −1,308.0% |
| 2023 | $253.57K | −$220.98K | −$5.15M | −$3.77M | −1,485.1% |
| 2022 | $223.21K | −$209.16K | −$1.75M | −$6.18M | −2,769.5% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
SXTP Valuation vs Biotechnology Median
Median of 608 stocks| Metric | SXTP | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 2.58 | 13.30 | 0.2x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B